CytomX Therapeutics, Inc.’s $125 Million Follow-On Offering

Davis Polk advised the joint book-running managers in connection with the $125 million public offering of common stock of CytomX Therapeutics, Inc. The shares are listed on the NASDAQ Global Select Market under the symbol “CTMX.”

Goldman Sachs & Co. LLC, Citigroup and Barclays acted as joint book-running managers on the offering.

CytomX Therapeutics is a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform.

The Davis Polk corporate team included partner Alan F. Denenberg (Picture) and associates Amy Tu and Ali DeGolia. The tax team included partner Rachel D. Kleinberg. Partner David R. Bauer and associates Bonnie Chen and Elizabeth R. Diggs provided intellectual property and technology advice.

Involved fees earner: Alan Denenberg – Davis Polk & Wardwell; Amy Tu – Davis Polk & Wardwell; Ali DeGolia – Davis Polk & Wardwell; Rachel Kleinberg – Davis Polk & Wardwell; David Bauer – Davis Polk & Wardwell; Bonnie Chen – Davis Polk & Wardwell; Elizabeth Diggs – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Barclays Bank; Citigroup Inc.; Goldman, Sachs & Co.;


Author: Ambrogio Visconti